AGING journal publishes high-impact research papers of general interest and biological significance in all fields of aging research including but not limited to cellular senescence, organismal aging, age-related diseases, DNA damage response and repair, genetic control of aging from yeast to mammals, regulation of longevity, evolution of aging, anti-aging strategies and drug development and especially the role of signal transduction pathways in aging and potential approaches to modulate these signaling pathways to extend lifespan.
The basic criterion for considering papers is their impact on aging research.
In addition to primary research articles in three formats (Priority Reports, Research Articles, Theory Articles), AGING publishes Reviews, Mini-reviews, Perspectives, Commentaries and Letters to the Editor.
All submissions are initially evaluated in depth by the editors. Papers that do not conform to the general criteria for publication will be returned to the authors without detailed review, typically within 2-4 days. Otherwise, manuscripts will be sent to 2-3 reviewers who have agreed in advance to assess the paper rapidly. The editors will make every effort to reach decisions on these papers within 3 weeks of the submission date. If revisions are a condition of publication, we generally allow 3 months for revisions and consider only one revised version of the paper.
Submit an article at: http://aging.msubmit.net.
If you would like editorial input on whether your paper might be a strong candidate for consideration at AGING, you can send a presubmission inquiry. This should include an abstract plus a brief description of the results and an explanation of the interest and significance to the broad readership of AGING and be emailed to firstname.lastname@example.org. We try to respond to these inquiries within 1-2 days.
AGING journal follows the International Committee of Medical Journal Editors' uniform requirements for manuscripts. Please click here for the full text http://www.icmje.org/icmje-recommendations.pdf
Peer Review Process
All submissions will undergo an unbiased and timely peer review process. The contents of manuscripts are considered as privileged. All Editors and reviewers are required to maintain strict confidentiality concerning all manuscripts. Details regarding a paper's status are known only to the Editor-in Chief, the Editorial Board (if applicable) and Editorial staff. Identities of reviewers, or any information that could reveal their identities, will not be revealed to the authors in order to maintain anonymity during the review process.
You may suggest 3-5 potential reviewers and 1-2 suitable members of the editorial board. You may exclude up to 5 potential reviewers
Copyright and License Policies
AGING applies the Creative Commons Attribution License (CCAL) to all works we publish (read the human-readable summary or the full license legal code). Under the CCAL, authors retain ownership of the copyright for their article, but authors allow anyone to download, reuse, reprint, modify, distribute, and/or copy articles in Aging journal, so long as the original authors and source are cited.
No permission is required from the authors or the publishers.
In most cases, appropriate attribution can be provided by simply citing the original article. If the item you plan to reuse is not part of a published article (e.g., a featured issue image), then please indicate the originator of the work, and the volume, issue, and date of the journal in which the item appeared. For any reuse or redistribution of a work, you must also make clear the license terms under which the work was published. This broad license was developed to facilitate open access to, and free use of, original works of all types. Applying this standard license to your own work will ensure your right to make your work freely and openly available.
Upon publication, AGING is intended to deposit all articles in PubMed Central. This complies with the policies of funding agencies, such as the National Institutes of Health in the United States, the Wellcome Trust and the Research Councils in the United Kingdom, and the Deutsche Forschungsgemeinschaft in Germany, which request or require deposition of the published articles that they fund into publicly available databases.
For queries about the license, please contact us at email@example.com.
The corresponding author is responsible for ensuring that all appropriate contributors are listed as authors and that all authors have agreed to the manuscript's content and its submission to AGING. In a case where we become aware of an authorship dispute, authorship must be approved in writing by all of the parties.
Conflict of Interest
The authors should indicate conflicts of interests and sources of financial support. Conflict of interest exists when an author (or the authors institution), reviewer, or editor has financial or personal relationships that inappropriately influence (bias) his or her actions. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment. Financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony) as well as personal relationships and academic competition must be declared. The authors declare conflicts of interests and sources of financial support as acknowledgment.
Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be published unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. A patient who is identifiable must be shown the manuscript to be published. Identifying details should be omitted if they are not essential. If identifying details are altered, editors should be informed. When informed consent has been obtained it should be indicated in the published article as: Informed consent has been obtained.
Human and animal rights. Ethical statment
All research involving human participants must have been approved by the authors' institutional review board or equivalent committee(s) and that board must be named by the authors in the manuscript. For research involving human participants, informed consent must have been obtained (or the reason for lack of consent explained, e.g. the data were analyzed anonymously) and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from their ethics committee or institutional review board indicating the approval of the research. All animal work must have been conducted according to relevant national and international guidelines. In accordance with the recommendations of the Weatherall report, "The use of non-human primates in research." we specifically require authors to include details of animal welfare and steps taken to ameliorate suffering in all work involving non-human primates. At the beginning of the Methods section of your manuscript (with the subheading Ethics Statement) enter: Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors' institutional review board.
Distribution of Materials and Data
One of the terms of publishing in AGING is that authors be willing to distribute any materials and protocols used in the published experiments to qualified researchers for their own use. If there are restrictions to the availability of any materials, data, or information, these must be disclosed in the cover letter and the Experimental Procedures section of the manuscript at the time of submission.
Nucleic acid and protein sequences, macromolecular structures determined by X-ray crystallography (along with structure factors), and microarray data must be deposited in the appropriate public database and must be accessible without restriction from the date of publication. An entry name or accession number must be included as the last paragraph of the Experimental Procedures section in the final version of the manuscript. Microarray data should be MIAME compliant (for guidelines see http://www.mged.org/Workgroups/MIAME/miame.html).
Interaction with Members of the Press for Papers in Press
Authors are free to talk with the press starting on the day of acceptance. We also allow authors to discuss their work in press with other scientific journals for purposes of coverage in review material. If your press office wishes to issue a press release, they may do that.
Galley Proofs are available upon publication in advances. The authors may be allowed to make corrections until full text paper is submitted to PubMed Central.
To provide open access, AGING journal uses a business model in which expenses - including those of peer review, journal production, and online hosting and archiving - are recovered in part by charging a journal-specific publication fee to the authors or research sponsors for each article they publish.
Publication fee of $2300 is applied to Research Papers and $1200 to Reviews. There should be no more than 15 figures and/or tables (including supplementary figures/tables). There are charges $80 for each additional figure/table. There is no fee for authors of invited Perspectives, Editorials and Commentaries.
We follow the WHO definition of a clinical trial. "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc"
AGING supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration. All trials initiated after 1 July 2005 must be registered prospectively in a publicly accessible registry (i.e., before patient recruitment has begun), or they will not be considered for publication. For trials initiated before 1 July 2005, all trials must be registered before submission to our journals. See the ICMJE faq on trial registration on trial registration for further details. The WHO's list of approved registries is listed here http://www.who.int/ictrp/network/list_registers/en/index.html.
Authors of randomized controlled trials must adhere to the CONSORT reporting guidelines appropriate to their trial design. Please check the CONSORT statement Web site for information on the appropriate guidelines for specific trial types. Before the paper can enter peer review authors must: 1) name in the paper trial registry, trial registration number, and IRB and 2) provide a copy of the trial protocol and a completed CONSORT checklist as supporting files. The CONSORT flow diagram must be included as Figure 1. Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and AGING reserves the right to ask for a copy of the patient consent form. Information on statistical methods or participants beyond what is indicated in the CONSORT statement should be reported in the Methods section.
Systematic Reviews and Meta-Analyses of Randomized Controlled Trials
Reports of meta-analyses of randomized controlled trials (RCTs) should use the QUOROM statement as a guide (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al.  Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. Lancet 354: 1896; 1900) and include a copy of the QUOROM checklist (27KB PDF).
Reports of studies of diagnostic accuracy should conform to the STARD requirements.
For reports of epidemiological studies, you should consult the STROBE initiative.
Reports of microarray experiments should conform to the MIAME guidelines and the data from the experiments must be deposited in a publicly accessible database.
Human and Animal Research
All research involving humans and animals must have been approved by the authors' institutional review board or equivalent committee and that board named by the authors. In the case of human participants, informed consent must have been obtained and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from the ethics committee or institutional review board indicating their approval of the research. We also encourage authors to submit a sample of a patient consent form and may require submission of completed forms on particular occasions.
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should, as much as possible:
In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: "Caucasian" should be changed to "white" or "of [Western] European descent" (as appropriate); "cancer victims" should be changed to "patients with cancer".
AGING fully supports the established standards of the fields that it covers. Some of these are detailed below:
The use of standardized nomenclature in all fields of science and medicine is an essential step toward the integration and linking of scientific information reported in published literature. We will enforce the use of correct and established nomenclature wherever possible: We strongly encourage the use of SI units. If you do not use these exclusively, please provide the SI value in parentheses after each value. Species names should be italicized (e.g., Homo sapiens) and the full genus and species must be written out in full, both in the title of the manuscript and at the first mention of an organism in a paper; after that, the first letter of the genus name, followed by the full species name may be used. Genes, mutations, genotypes, and alleles should be indicated in italics. Use the recommended name by consulting the appropriate genetic nomenclature database, e.g., HUGO. It is sometimes advisable to indicate the synonyms for the gene the first time it appears in the text. Gene prefixes such as those used for oncogenes or cellular localization should be shown in roman: v-fes, c-MYC, etc.
The Recommended International Non-Proprietary Name (rINN) of drugs should be provided.
All appropriate datasets, images, and information should be deposited in public resources. Please provide the relevant accession numbers (and version numbers, if appropriate). Accession numbers should be provided in parentheses after the entity on first use. Suggested databases include, but are not limited to:
In addition, as much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:
Providing accession numbers allows linking to and from established databases and integrates your article with a broader collection of scientific information.
Editorials are generally invited. Brief discussions of recently published papers in Aging and elsewhere. There is the strict limit - 850 words and no more than 7 references. Special reference format: 1 author et al, no titles.
Research papers generally contain the following sections in this order: Title, Authors, Affiliations, Contact Information, Key words (4-6), Abstract, Introduction, Results, Discussion, Methods, Acknowledgements, References, Figure and Table Legends.
The list of references should be numbered consecutively according to the first time mentioned within the article. Cite only the number assigned to the reference: For example: "according to Campisi ". Use [ ] not ( ). References should include only articles that are published or in press. Unpublished data, submitted manuscripts, abstracts, and personal communications should be cited within the text only. Personal communication should be documented with a letter of permission.
The Theory format is intended for articles that main conclusions are based on computational, theoretical, or analytical approaches and/or re-interpretation of existing published data. Theory article will explain previously unexplained phenomena, provide mechanism for observations, integrate separate facts in one model, to substitute general rules for thousands of independent facts. The conclusions must be novel compared with otherwise published paradigms. The authors may include additional experiments to support points that lack already published supporting data. Theory articles must also suggest experimentally testable predictions. They follow the same length guidelines as Research articles.
Discussions and Letters to the Editors
Format may vary.
Topical discussion of recent scientific advances. May contain clarifications, new interpretations. May include both published and unpublished own data to clarify the point. Any number of figures. Must include Abstract and Key words. Should be well referenced, with a minimal number of references above 70. There is no upper limit on the number of references.
Authors may suggest a Review on a broad topic of general interest. Should be well referenced, with a minimal number of references above 90. Reviews should include 1-6 figures, diagrams or cartoons.
Mega-Reviews and Books
Comprehensive coverage of the topic. Any number of figures. Color figures are especially welcome. Should be well referenced, with a minimal number of references above 300. There is no upper limit on the number of references.
Each submission should be accompanied by a cover letter, which should contain a brief explanation of the work impact. A cover letter may contain suggestions for appropriate reviewers.
Research articles generally contain the following sections in this order: Title, Authors, Affiliations, Contact Information, Running title, Key words (6-7), Abstarct, Introduction, Results, Discussion, Methods, Acknowledgements, References, Figure and Table Legends, Figures and Tables, Supplemental Data. The text (Title through Legends) should be provided as one document, which may also contain the Tables. Figures should be provided separately. Supplemental Data should be provided separately.
There is no word count limit for research articles. An article may contain up to 15 figures and/or tables. Gene symbols should be italicized; protein products of the loci are not italicized. Nonstandard abbreviations should be defined when first used in the text. Use of abbreviations should be kept at a minimum. Manuscript file types that we can accept for submission include Word and RTF.
The text should be double spaced and pages should be numbered. Although summaries need to be entered as text files separate from the body of the manuscript during the online submission process, they should also be included within the manuscript file as usual.
Manuscripts that do not conform to the format guidelines may be returned to the authors for reformatting.
Preparation of Specific Sections
The title should convey the conceptual significance of the paper to a broad readership.
Author names should be spelled out rather than set in initials. Authors should be footnoted to corresponding affiliations. Affiliations should contain the following core information: department(s)/subunit(s); institution; city, state/region, postal code; country.
The contact line should include the email address and phone/fax numbers of the corresponding author. The published corresponding author is responsible for ensuring adherence to all editorial and submission policies and for any communications that may result post-publication.
Footnotes are only allowed on page 1 of the text (and in tables). They may include a present address or statement of equal contribution to the manuscript.
The Abstract consists of a single paragraph of fewer than 200 words. It should clearly convey the conceptual advance and significance of the work to a broad readership. References should not be cited in the Summary.
The Introduction should be succinct, with no subheadings, and should present the background information necessary to provide a biological context for the results.
This section should be divided with subheadings.
The Discussion should explain the significance of the results and place them into a broader context. This section may in some cases be combined with the Results section.
The Methods section needs to include sufficient detail so that readers can understand how the experiments were done, and so that all procedures can be repeated, in conjunction with cited references. This section should also include a description of any statistical methods employed in the study.
This section may acknowledge contributions from non-authors, list funding sources, and should include a statement of any conflict of interests.
The list of references should be numbered consecutively according to the first time mentioned within the article. Cite only the number assigned to the reference: For example, according to Campisi . Use [ ] not ( ). References should include only articles that are published or in press. Unpublished data, submitted manuscripts, abstracts, and personal communications should be cited within the text only. Personal communication should be documented by a letter of permission.
Please use the following style for references:
Papers (except Editorials):
Please use the following style for references in all types of papers except Editorials:
1) Article in a periodical (strictly, no variation is allowed):
1. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, and Campisi J. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging. 2009; 1:402-411.
Note: "et al." should only be used after 13 authors.
Please use a special reference format: 1 author et al, no titles.